INTRODUCTION
============

Duchenne muscular dystrophy (DMD) is a hereditary muscle-wasting disorder afflicting ∼1 in 3500 males. DMD is caused by absence of the costameric protein dystrophin from the sarcolemma of skeletal muscle fibers, leading to sarcolemmal mechanical instability, membrane rupture during muscle contraction, pathological influx of extracellular Ca^2+^ into the muscle fiber interior, resultant hyperactivity of Ca^2+^-dependent proteases, and widespread misregulated proteolysis of muscle cytoskeletal proteins ([@B5]; [@B49]). Key players in the progression of Ca^2+^-dependent proteolysis in dystrophic muscle are the calpains, a ubiquitously expressed and well-conserved family of Ca^2+^-dependent cysteine proteases ([@B59]). Total calpain levels are elevated in the muscles of dystrophin-deficient *mdx* mice (a well-characterized animal model of DMD) as compared with wild-type (WT) mice, and this increase is primarily driven by elevated concentrations of m-calpain ([@B56]). Moreover, myotubes differentiated from *mdx* myoblasts, isolated *mdx* muscle fibers, and intact *mdx* soleus muscles all exhibit heightened calpain-mediated proteolysis when compared with their WT counterparts ([@B60]; [@B1]; [@B38]; [@B17]). Proteolysis in *mdx* myotubes can be attenuated by experimentally lowering external \[Ca^2+^\], treatment with Ca^2+^ leak channel antagonists, or treatment with calpain inhibitors, but inhibitors of lysosomal and proteosomal pathways have no effect ([@B1]). Despite the clear role of calpains in establishing the dystrophic phenotype, the relative contributions of the various proteolytic pathways to muscle structure and in vivo progression of DMD, as well as the relative utilities of these pathways as therapeutic targets, are highly controversial ([@B11]; [@B6]; [@B54], [@B53]; [@B10]; [@B61]).

Given the complex regulatory mechanisms that govern calpain activity in vivo, direct evidence implicating specific intrasarcomeric calpain substrates in the pathogenesis and progression of DMD-induced muscle wasting is elusive. One potential intrasarcomeric target of calpain-mediated proteolysis in dystrophic muscle is the tropomodulin (Tmod) family of actin filament pointed-end--capping proteins. Tmods are dynamic caps that regulate actin subunit association and dissociation from pointed ends in a tropomyosin-dependent manner ([@B62], [@B63]), thereby controlling actin filament lengths and stability in a diverse assortment of cell types ([@B65]). In the case of skeletal muscle sarcomeres, two sarcomeric Tmod isoforms (Tmod1 and Tmod4) localize to either side of the M-line, along the periphery of the H-zone, where they cap the pointed (free) ends of the thin filaments ([@B16]; [@B2]; [@B24], [@B23]; [@B21]). Sarcomeric Tmods maintain thin filament stability and correctly specified thin filament lengths in *Drosophila* and vertebrate cardiac muscles via their interactions with terminal tropomyosins and their ability to regulate actin subunit exchange at pointed ends ([@B28]; [@B58]; [@B34]; [@B36]; [@B37]; [@B42]). In skeletal muscle, sarcomeric Tmods are proposed to fine-tune the lengths of the nebulin-free distal segments of the thin filaments, independent of the lengths of the nebulin-coated proximal segments of the thin filaments ([@B22]). Given Tmods' sterically accessible location within the sarcomere, as well as the fact that calpains can proteolyze a host of other actin-binding proteins in both muscle and nonmuscle cells ([@B8]; [@B25]), we hypothesized that sarcomeric Tmods may be calpain substrates in DMD, with proteolysis of Tmods leading to misspecified thin filament lengths in dystrophic skeletal muscle. Such a mechanism would represent a novel and physiologically relevant defect in DMD because myofilament lengths determine the sarcomere length ranges at which muscles can establish actomyosin cross-bridges and produce contractile force ([@B22]).

To directly address the question of whether calpain-mediated proteolysis of Tmods contributes to altered thin filament lengths and disease pathogenesis in DMD, we studied the responses of Tmods to calpain-mediated proteolysis in vitro and in dystrophic muscles in vivo. In this study, we show that both Tmod1 and Tmod4 are equally sensitive to calpain-mediated proteolysis in vitro, but Tmod1 is about an order of magnitude more sensitive to calpain-mediated proteolysis than Tmod4 when associated with myofibrils in situ. In *mdx* mice, an increase in m-calpain levels in dystrophic soleus muscle is associated with dramatic loss of Tmod1 (but not Tmod4) from the thin filament pointed ends, resulting in ∼11% increase in thin filament lengths as determined by distributed deconvolution (DDecon) analysis of fluorescence images. We also examined Tmod isoform loss in *mdx*/mTR mice, a more severe mouse model of DMD lacking both dystrophin and the telomerase RNA component, characterized by short telomeres and dramatically impaired regenerative capacity of intramuscular stem cells ([@B52]). In *mdx*/mTR mice, Tmod1 disappears from the thin filament pointed ends in both tibialis anterior (TA) and soleus muscles, whereas Tmod4 additionally disappears from soleus muscle, resulting in thin filament length increases of ∼10 and ∼12% in the TA and soleus, respectively. Of note, comparison of *mdx* and *mdx*/mTR soleus muscles showed that graded losses of sarcomeric Tmods do not result in correspondingly graded increases in thin filament lengths, suggesting the existence of a ceiling on maximum thin filament length in vivo. Collectively these results delineate a novel mechanism contributing to skeletal muscle dysfunction in DMD in which calpain-mediated proteolysis of Tmods leads to actin subunit addition at thin filament pointed ends and increased thin filament lengths, and the types of muscles affected by this mechanism depend on the severity of DMD pathology.

RESULTS
=======

Sarcomeric Tmods are proteolytic substrates of m-calpain
--------------------------------------------------------

Actin cytoskeletal proteins are frequently calpain cleavage substrates under a wide variety of pathological conditions ([@B8]; [@B25]), but it is unknown whether sarcomeric proteins, such as Tmod1 and Tmod4, are also calpain cleavage substrates. To directly test whether m-calpain can proteolyze Tmod1 and/or Tmod4 in situ, we prepared isolated skeletal myofibrils from WT TA and extensor digitorum longus (EDL) muscles and treated these myofibrils with 40 μg/ml m-calpain activated by millimolar Ca^2+^. Immunostaining of m-calpain--treated myofibrils revealed disappearance of both Tmod1 and Tmod4 from the pointed ends of phalloidin-stained thin filaments in virtually all myofibrils examined, whereas the striated staining patterns of F-actin and α-actinin were unaffected ([Figure 1, A and B](#F1){ref-type="fig"}). Western blotting confirmed depletion of Tmod1 and Tmod4 from the m-calpain--treated myofibrils, with no change in total actin levels, and Coomassie blue staining revealed no gross changes in myofibrillar protein composition resulting from m-calpain treatment ([Figure 1C](#F1){ref-type="fig"}). Note that Tmod depletion determined by immunofluorescence appeared more striking than Tmod depletion determined by Western blotting, which may be due to either the narrower detection range of immunofluorescence or the inability of immunofluorescence to detect any Tmod protein that may have been extracted or solubilized from the washed myofibrils. We also examined myofibrils treated with either Ca^2+^ or m-calpain alone, as well as m-calpain in the presence of Ca^2+^ and a specific inhibitor (calpeptin). As expected, these control treatments had no effect on the localizations or protein levels of Tmod1 and Tmod4 ([Figure 1, A--C](#F1){ref-type="fig"}).

![Sarcomeric Tmods show differential sensitivities to m-calpain--induced proteolysis in situ. (A, B) Isolated skeletal myofibrils from TA and EDL muscles from 2-mo-old WT mice were treated with 10 mM Ca^2+^, 40 μg/ml m-calpain, 40 μg/ml m-calpain activated by 10 mM Ca^2+^, or 40 μg/ml m-calpain activated by 10 mM Ca^2+^ in the presence of 10 μg/ml calpeptin. Myofibrils were then immunostained for either (A) Tmod1 or (B) Tmod4, immunostained for α-actinin, and phalloidin-stained for F-actin. Bars, 1 μm. (C) Coomassie blue--stained gel and Western blots of myofibrils treated as indicated, probed using antibodies against m-calpain, Tmod1, Tmod4, and actin. (D) Isolated skeletal myofibrils were treated with increasing concentrations of m-calpain activated by 10 mM Ca^2+^. Myofibrils were then subjected to Western blotting and probed using antibodies against Tmod1, Tmod4, α-actinin, and actin. (E) Quantification of Western blots for Tmod1 and Tmod4. Error bars reflect mean ± SEM of *n* = 3 independent experiments.](852fig1){#F1}

Next we tested whether Tmod1 and Tmod4 have differential sensitivities to m-calpain--induced proteolysis in situ by treating myofibrils with increasing concentrations of m-calpain and performing Western blots for Tmod1 and Tmod4. Quantitation of these Western blots showed that myofibrillar Tmod1 had ∼10-fold greater sensitivity to m-calpain--induced proteolysis as compared with myofibrillar Tmod4 ([Figure 1, D and E](#F1){ref-type="fig"}). This result contrasts with the similar sensitivities of purified recombinant Tmod1 and Tmod4 to m-calpain--induced proteolysis in vitro ([Figure 2](#F2){ref-type="fig"}).

![Purified sarcomeric Tmods show identical sensitivities to m-calpain--induced proteolysis in vitro. Constant amounts of recombinant human Tmod1 or mouse Tmod4 were treated with increasing concentrations of m-calpain activated by 10 mM Ca^2+^ for 1 h at room temperature. Mixtures were then electrophoresed on SDS--PAGE gels, stained with Coomassie blue, and densitometrically quantified. Error bars reflect mean ± SEM of *n* = 3 independent experiments.](852fig2){#F2}

The differential susceptibilities of Tmod1 and Tmod4 to m-calpain--induced proteolysis in situ may be due to different conformations of Tmod1 and Tmod4 at the thin filament pointed ends, leading to differential accessibility of proteolytic epitopes; this may be mediated by sarcomeric Tmods' differential affinities for striated muscle tropomyosins ([@B24]). Alternatively, the apparent lesser susceptibility of Tmod4 to m-calpain--induced proteolysis may be due to a greater abundance of Tmod4 than Tmod1 in TA and EDL myofibrils. To distinguish between these possibilities, we performed quantitative Western blotting of isolated skeletal muscle myofibrils prepared from TA and EDL muscles and determined the molar ratio of sarcomeric Tmods (Supplemental Figure S1). In three separate experiments, the ratio of Tmod4 to Tmod1 varied from 8.6 to 9.6 ([Table 1](#T1){ref-type="table"}), indicating that Tmod4 is almost an order of magnitude more abundant than Tmod1 on the thin filament pointed ends. In these experiments, the molar ratio of actin to total sarcomeric Tmods varied from 187 to 208, corresponding to ∼2 Tmods/pointed end ([Table 1](#T1){ref-type="table"}). This result is somewhat greater than the 1.2--1.6 Tmods/pointed end previously determined via quantitative immunoprecipitation of Tmods from isolated myofibrils using a rabbit polyclonal antibody prepared against Tmod1 ([@B16]). This discrepancy is most likely due to the fact that the immunoprecipitations were performed before the identification of Tmod4 ([@B2]), and the Tmod1 antibody failed to completely immunoprecipitate Tmod4. We conclude that the apparent lesser susceptibility of Tmod4 to m-calpain--induced proteolysis in situ is due to the greater abundance of Tmod4 than Tmod1 in TA and EDL myofibrils. Moreover, these results collectively identify Tmod1 and Tmod4 as novel proteolytic substrates of m-calpain, implicating these Tmods as proteolytic targets of endogenous m-calpain in DMD-induced muscle degeneration.

###### 

Stoichiometry of sarcomeric Tmods associated with thin filaments in mouse TA and EDL myofibrils.

  Experiment   Tmod1/gel sample (ng/μl)^a^   Tmod4/gel sample (ng/μl)^a^   Actin/gel sample (ng/μl)^b^   Tmod4/Tmod1 (mol/mol)   Actin/sarcomeric Tmods (mol/mol)   Sarcomeric Tmods/pointed end^c^
  ------------ ----------------------------- ----------------------------- ----------------------------- ----------------------- ---------------------------------- ---------------------------------
  1            0.49 ± 0.03                   4.25 ± 0.35                   985 ± 45                      8.6                     208                                1.8
  2            0.36 ± 0.05                   3.26 ± 0.22                   722 ± 15                      8.8                     187                                2.1
  3            0.39 ± 0.03                   3.84 ± 0.43                   780 ± 68                      9.6                     193                                2.1

^a^Amounts of sarcomeric Tmods were determined by quantitative Western blotting and densitometry of skeletal muscle myofibrils (1--8 μl of gel sample) electrophoresed alongside purified recombinant protein standards (0.25--4 ng) on the same gel. Tmod1 or Tmod4 protein standards were mixed with *Tmod1^−/−^* or *Tmod4^−/−^* TA muscle lysates, respectively, to equalize the effects of endogenous non-Tmod proteins on the Western transfer efficiencies of endogenous vs. recombinant purified Tmods. SDs reflect three or four different myofibril volumes from different lanes on the same blot (Supplemental Figure S1).

^b^Amounts of actin were determined by densitometry of Coomassie blue--stained gels containing skeletal muscle myofibrils (1--8 μl of gel sample) electrophoresed alongside rabbit skeletal muscle actin standards (0.25--4 μg) on the same gel. SDs correspond to three or four different myofibril volumes from different lanes on the same gel (Supplemental Figure S1).

^c^Numbers of Tmods/pointed end were calculated based on thin filament length of 1.11 μm and 13 actin subunits per 37 nm of thin filament ([@B16]; [@B24]).

Soleus muscles from *mdx* mice exhibit proteolysis of Tmod1 and increased thin filament lengths
-----------------------------------------------------------------------------------------------

DMD pathogenesis is characterized by sarcolemmal fragility, membrane rupture during muscle contraction, influx of extracellular Ca^2+^ into the muscle fiber interior, and hyperactivity of Ca^2+^-dependent proteases, including calpains ([@B5]). It was previously shown that leg muscle from the *mdx* mouse model of DMD exhibits elevated concentrations of m-calpain ([@B56]), although a systematic comparison of different muscle types was not performed. Therefore we used Western blots to measure m-calpain levels in TA, EDL, and soleus muscles from WT and *mdx* mice; these muscles were chosen because they reflect a diversity of muscle fiber recruitment levels and architectures ([@B7]). Results show that *mdx* soleus muscle, but not *mdx* TA or EDL muscle, exhibits greater than twofold increase in m-calpain levels as compared with WT muscle ([Figure 3, A and B](#F3){ref-type="fig"}). Thus, elevated m-calpain levels in DMD muscles appear to be primarily characteristic of heavily recruited, slow-twitch muscles such as the soleus.

![Elevated levels of m-calpain are associated with decreased levels of sarcomeric Tmods in dystrophic muscles. (A) Western blots of homogenates of TA, EDL, and soleus muscles from 2-mo-old WT and *mdx* mice were probed using antibodies against m-calpain, Tmod1, and Tmod4. GAPDH was used as a loading control. (B) Quantification of Western blots. Error bars reflect mean ± SEM of *n* = 4 lanes/genotype within a single blot. (C) Western blots of homogenates of TA and soleus muscles from 2-mo-old WT and *mdx*/mTR mice were probed using antibodies against m-calpain, Tmod1, and Tmod4. GAPDH was used as a loading control. (D) Quantification of Western blots. Error bars reflect mean ± SEM of *n* = 3 lanes/genotype within a single blot. (E) RT-PCR of *Tmod1* and *Tmod4* mRNA transcripts from homogenates of TA, EDL, and soleus muscles from 2-mo-old WT and *mdx* mice. *GAPDH* was used as a loading control. (F) Quantification of RT-PCR. Error bars reflect mean ± SEM of *n* = 3 lanes/genotype within a single gel. \**p* \< 0.05.](852fig3){#F3}

To determine whether increased m-calpain levels in *mdx* soleus muscle are associated with proteolysis of sarcomeric Tmods in vivo, we immunostained longitudinal cryosections of TA and soleus muscles from postnecrotic (2-mo-old) WT and *mdx* mice for Tmod1 and Tmod4. In WT TA and soleus muscles, both Tmod1 and Tmod4 exhibited their well-established striated staining patterns of periodic doublets, corresponding to the pointed ends of phalloidin-stained thin filaments ([Figures 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). Tmod1 and Tmod4 did not colocalize with m-calpain, which localizes to Z-line-flanking and M-line stripes (Supplemental Figure S2), possibly associated with the sarcoplasmic reticulum (SR; [@B20]). Of note, Tmod1 did not exhibit a striated staining pattern in *mdx* soleus muscle, instead showing a diffuse and punctate pattern consistent with proteolytic degradation ([Figure 4B](#F4){ref-type="fig"}). By contrast, Tmod4 staining appeared to be unaffected in *mdx* soleus muscle, where it showed a pattern of striations at the thin filament pointed ends, indistinguishable from WT soleus muscle ([Figure 5B](#F5){ref-type="fig"}). To confirm these results, we performed Western blots for Tmod1 and Tmod4. In agreement with the immunostaining data, Tmod1 showed ∼40% decrease in protein levels in *mdx* soleus muscle, but Tmod1 levels were unchanged in *mdx* TA and EDL muscles ([Figure 3, A and B](#F3){ref-type="fig"}). Similarly, Tmod4 levels were unchanged in *mdx* TA, EDL, and soleus muscles ([Figure 3, A and B](#F3){ref-type="fig"}). Reverse transcription (RT)-PCR analysis showed identical *Tmod1* and *Tmod4* mRNA levels in WT and *mdx* muscles, indicating that reduced Tmod1 protein levels in *mdx* soleus muscle were not due to reduced transcription of the *Tmod1* gene ([Figure 3, E and F](#F3){ref-type="fig"}). We conclude that elevated m-calpain levels in *mdx* soleus muscle are associated with proteolytic degradation of Tmod1. This finding is consistent with the greater proteolytic sensitivity of myofibrillar Tmod1 as compared with Tmod4 in situ ([Figure 1](#F1){ref-type="fig"}).

![Soleus muscle from *mdx* mice and both TA and soleus muscles from *mdx*/mTR mice exhibit loss of Tmod1 from thin filament pointed ends. (A, B) Longitudinal cryosections of (A) TA and (B) soleus muscles from 2-mo-old WT, *mdx*, and *mdx*/mTR mice were immunostained for Tmod1 and α-actinin and phalloidin-stained for F-actin. P, thin filament pointed ends; Z, Z-line. Bars, 1 μm.](852fig4){#F4}

![Soleus muscle from *mdx*/mTR mice exhibits loss of Tmod4 from thin filament pointed ends. (A, B) Longitudinal cryosections of (A) TA and (B) soleus muscles from 2-mo-old WT, *mdx*, and *mdx*/mTR mice were immunostained for Tmod4 and α-actinin and phalloidin-stained for F-actin. P, thin filament pointed ends; Z, Z-line. Bars, 1 μm.](852fig5){#F5}

Pointed-end capping by Tmod1 restricts actin subunit association and dissociation from the pointed ends of actin filaments ([@B62], [@B63]), and the extent of capping by Tmod1 is inversely related to thin filament length in sarcomeres of *Drosophila* and vertebrate cardiac muscles ([@B28]; [@B58]; [@B34]; [@B37]; [@B21]). Therefore we speculated that depletion of Tmod1 from *mdx* soleus muscle would allow actin subunit addition from the cytoplasmic pool onto the thin filament pointed ends, leading to increased thin filament lengths. To test this, we performed DDecon analysis of line scans from fluorescence images to measure thin filament lengths from the breadth of the phalloidin signal and the distances of sarcomeric Tmods from the Z-line ([@B35]; [@B22]). Consistent with normal Tmod immunostaining and protein levels in *mdx* TA muscle, thin filament lengths in *mdx* TA muscle were indistinguishable from those in WT TA muscle ([Table 2](#T2){ref-type="table"}). On the other hand, thin filament lengths in *mdx* soleus muscle were ∼12% greater than in WT soleus muscle (1.39 ± 0.10 vs. 1.24 ± 0.06 μm, respectively; [Table 2](#T2){ref-type="table"}), consistent with reduced Tmod1 levels in *mdx* soleus muscle. We conclude that calpain-mediated proteolysis of Tmod1 in *mdx* soleus muscle leads to thin filament elongation from pointed ends and increased thin filament lengths.

###### 

Thin filament lengths in 2-mo-old mice determined by DDecon analysis of fluorescence images.

                                    TA            Soleus                                                      
  ---------------- ---------------- ------------- ------------- --------------- ------------- --------------- ---------------
  Phalloidin       Mean ± SD (μm)   1.00 ± 0.04   1.01 ± 0.07   1.10 ± 0.05\*   1.15 ± 0.03   1.28 ± 0.09\*   1.29 ± 0.06\*
                   Min-max (μm)     0.94--1.09    0.86--1.11    0.98--1.18      1.06--1.23    1.11--1.47      1.14--1.46
                   n                87            107           67              61            52              50
  Tmod             Mean ± SD (μm)   1.06 ± 0.04   1.08 ± 0.02   1.16 ± 0.06\*   1.24 ± 0.06   1.39 ± 0.10\*   n.d.
                   Min-max (μm)     0.98--1.13    1.03--1.12    1.05--1.28      1.07--1.34    1.15--1.58      n.d.
                   n                68            86            60              54            64              n.d.
  Nebulin M1M2M3   Mean ± SD (μm)   0.93 ± 0.03   0.93 ± 0.05   0.94 ± 0.07     0.92 ± 0.04   0.93 ± 0.04     0.94 ± 0.05
                   Min-max (μm)     0.88--0.98    0.86--1.03    0.85--1.06      0.82--0.98    0.85--1.01      0.86--1.05
                   n                35            47            27              36            45              32

Parameters correspond to the breadth of phalloidin staining and the distances of Tmod and nebulin M1M2M3 from the Z-line. In WT TA, *mdx* TA, and WT soleus muscles, Tmod lengths were determined from both Tmod1 and Tmod4 immunostaining. In *mdx* soleus and *mdx*/mTR TA muscles, Tmod lengths were determined from only Tmod4 immunostaining, due to the absence of striated Tmod1 immunostaining. In *mdx*/mTR soleus muscle, Tmod lengths were not determined (n.d.) due to the lack of striated Tmod1 and Tmod4 immunostaining. *n*, number of myofibrils.

\*Significant difference when compared with WT (*p* \< 0.01).

TA and soleus muscles from *mdx*/mTR mice exhibit proteolysis of Tmod1 and Tmod4 and increased thin filament lengths
--------------------------------------------------------------------------------------------------------------------

The usefulness of the *mdx* mouse as an animal model of DMD is restricted by its mild phenotype and normal lifespan, which are believed to be due to a host of mouse-specific compensatory responses, such as sustained postnatal up-regulation of utrophin ([@B33]; [@B15]; [@B26]) and robust proliferative capacity of intramuscular stem cells to replace necrotic fibers ([@B52]). Hence we examined Tmod isoform loss and measured thin filament lengths in *mdx*/mTR mice, a more severe animal model that recapitulates human DMD more accurately. In addition to lacking dystrophin, *mdx*/mTR mice lack the telomerase RNA component, leading to short telomeres and stem cell exhaustion during muscle regeneration ([@B52]). Immunostaining of longitudinal cryosections of *mdx*/mTR TA muscles revealed disappearance of Tmod1 from the thin filament pointed ends, reflecting a more severe phenotype than in *mdx* TA muscle, where Tmod1 localization was normal ([Figure 4A](#F4){ref-type="fig"}). Loss of Tmod1 from postnecrotic *mdx*/mTR TA muscle was due to DMD-induced proteolysis, and not absence of Tmod1 during myofibril assembly or muscle development, because TA muscles from prenecrotic (2-wk-old) *mdx*/mTR mice exhibited normal Tmod1 localization and correspondingly normal thin filament lengths (Supplemental Figure S3 and Supplemental Table S1). Tmod1 was also lost from the thin filament pointed ends in *mdx*/mTR soleus muscle, as in *mdx* soleus muscle ([Figure 4B](#F4){ref-type="fig"}). Tmod4 showed normal localization in *mdx*/mTR TA muscle, similar to *mdx* TA muscle, although slight attenuation of the Z-line-flanking, SR-associated Tmod4 striations was observed ([Figure 5A](#F5){ref-type="fig"}). By contrast, Tmod4 completely disappeared from the thin filament pointed ends in *mdx*/mTR soleus muscle, reflecting a more severe phenotype than in *mdx* soleus muscle, where Tmod4 localization was normal ([Figure 5B](#F5){ref-type="fig"}). Western blots confirmed that decreased protein levels of sarcomeric Tmods were associated with elevated m-calpain levels in TA and soleus muscles from *mdx*/mTR mice ([Figure 3, C and D](#F3){ref-type="fig"}) to a greater extent than in *mdx* soleus muscles ([Figure 3, A and B](#F3){ref-type="fig"}). Collectively these observations indicate that *mdx*/mTR muscles exhibit more severe calpain-mediated proteolysis of sarcomeric Tmods than *mdx* muscles, consistent with more pronounced DMD disease severity in *mdx*/mTR mice.

Enhanced proteolysis of sarcomeric Tmod isoforms in *mdx*/mTR muscles as compared with *mdx* muscles led us to speculate that *mdx*/mTR muscles would also exhibit more pronounced increases in thin filament lengths. To test this, we used DDecon analysis to measure thin filament lengths in *mdx*/mTR muscles. Consistent with proteolysis of Tmod1 in *mdx*/mTR TA muscle, thin filament lengths were ∼10% longer in *mdx*/mTR TA muscle than in WT muscle, unlike *mdx* TA muscle, where Tmod1 was not degraded ([Table 2](#T2){ref-type="table"}). Of interest, only Tmod1 was proteolyzed in *mdx* soleus muscle, whereas both Tmod1 and Tmod4 were proteolyzed in *mdx*/mTR soleus muscle, yet both *mdx* and *mdx*/mTR soleus muscles showed nearly identical increases in thin filament length of ∼12% ([Table 2](#T2){ref-type="table"}). This indicates that disappearance of two sarcomeric Tmod isoforms does not necessarily result in longer thin filament lengths than disappearance of a single sarcomeric Tmod isoform, and thin filament length is not a simple inverse function of pointed-end capping by sarcomeric Tmods in skeletal muscle. Collectively our DDecon measurements show that calpain-mediated proteolysis of sarcomeric Tmods leads to increased thin filament lengths in *mdx*/mTR TA and soleus muscles.

The N-terminal M1M2M3 domain of nebulin is normally localized in dystrophic skeletal muscle
-------------------------------------------------------------------------------------------

In skeletal muscle thin filaments, nebulin extends from its C-terminus in the Z-line to its N-terminal M1M2M3 domain at the end of the proximal segment, whereas the distal segment extends beyond the nebulin M1M2M3 domain and is capped by sarcomeric Tmods ([@B22]). It is uncertain whether the increases in thin filament lengths in dystrophic muscle are due to longer distal segments, longer proximal segments, or a combination of both. To distinguish among these possibilities, we immunostained longitudinal cryosections of TA and soleus muscles from WT, *mdx*, and *mdx*/mTR mice for the nebulin M1M2M3 domain and measured the distances of the nebulin M1M2M3 domain from the Z-line. In TA and soleus muscles of all three genotypes, the nebulin M1M2M3 domain localized in striations slightly proximal to the pointed ends of the thin filaments ([Figure 6](#F6){ref-type="fig"}), as expected ([@B9]; [@B24], [@B23]; [@B22]). The nebulin M1M2M3 striations were ∼0.92--0.94 μm from the Z-line in both TA and soleus muscles of all three genotypes, and no significant differences among the genotypes were detected ([Table 2](#T2){ref-type="table"}). Therefore the lengths of the nebulin-coated proximal segments are unchanged in *mdx* and *mdx*/mTR muscles, and the overall increases in thin filament lengths observed in these muscles are driven entirely by increases in the lengths of the nebulin-free, Tmod-capped distal segments.

![The N-terminal M1M2M3 domain of nebulin exhibits normal localization in *mdx* and *mdx*/mTR muscles. (A, B) Longitudinal cryosections of (A) TA and (B) soleus muscles from 2-mo-old WT, *mdx*, and *mdx*/mTR mice were immunostained for nebulin M1M2M3 and α-actinin and phalloidin-stained for F-actin. Note that F-actin extends further beyond nebulin M1M2M3 in soleus muscle than in TA muscle, consistent with longer distal segments in slow muscles and shorter distal segments in fast muscles ([@B22]). P, thin filament pointed ends; Z, Z-line. Bars, 1 μm.](852fig6){#F6}

SR-associated actin cytoskeletal proteins are normally localized in dystrophic skeletal muscle
----------------------------------------------------------------------------------------------

Tmod3, an SR-associated Tmod isoform, has been shown to structurally compensate for the absence of Tmod1 in *Tmod1^−/−^* skeletal muscle by dissociating from its SR compartment and relocating to the thin filament pointed ends, thereby maintaining normal thin filament lengths ([@B24]; [@B20]). To test whether SR-associated Tmod3 may also compensate for depletion of Tmod1 and/or Tmod4 in dystrophic muscles via a similar relocation-based mechanism, we immunostained longitudinal cryosections of TA and soleus muscles from WT, *mdx*, and *mdx*/mTR mice for Tmod3. Surprisingly, Tmod3 localized to Z-line-flanking and M-line stripes ([Figure 7A](#F7){ref-type="fig"}) in TA muscles of all three genotypes, indicative of Tmod3's normal localization in the SR ([@B20]). In soleus muscles of all three genotypes, Tmod3 also localized to Z-line-flanking stripes, with fainter M-line localization ([Figure 7B](#F7){ref-type="fig"}). Examination of highly stretched myofibrils in all three genotypes did not reveal any Tmod3 associated with the thin filament pointed ends that might have been obscured by the bright Tmod3 fluorescence at the M-line (unpublished data). Thus, in contrast to *Tmod1^−/−^* skeletal muscle, Tmod3 fails to cap Tmod1-free thin filament pointed ends and compensate for depletion of sarcomeric Tmods in dystrophic muscle.

![Tmod3 exhibits normal, SR-associated localization in *mdx* and *mdx*/mTR muscles. (A, B) Longitudinal cryosections of (A) TA and (B) soleus muscles from 2-mo-old WT, *mdx*, and *mdx*/mTR mice were immunostained for Tmod3 and α-actinin and phalloidin-stained for F-actin. M, M-line; Z, Z-line. Bars, 1 μm.](852fig7){#F7}

Tmod3 caps the pointed ends of cytoplasmic γ-actin (γ~cyto~-actin) filaments and interacts with nonmuscle tropomyosins and small ankyrin 1.5 to mechanically stabilize the SR membrane ([@B20]). Dystrophic muscles exhibit dramatic up-regulation of γ~cyto~-actin, presumably as a compensatory fortification response to sarcolemmal fragility ([@B30], [@B29]). On the basis of these observations, we speculated that depletion of sarcomeric Tmods from dystrophic muscle would result in incorporation of excess γ~cyto~-actin into the longer thin filaments, as observed in myofibrils from γ~cyto~-actin--overexpressing muscle ([@B31]). To test this, we immunostained longitudinal cryosections of TA and soleus muscles from WT, *mdx*, and *mdx*/mTR mice for γ~cyto~-actin. In TA muscles of all three genotypes, γ~cyto~-actin localized to Z-line-flanking and M-line stripes ([Figure 8A](#F8){ref-type="fig"}), consistent with its previously observed localization in the SR ([@B20]). In soleus muscles of all three genotypes, γ~cyto~-actin localized to a wide I-band stripe and lacked M-line localization ([Figure 8B](#F8){ref-type="fig"}), revealing the presence of different γ~cyto~-actin architectures in TA versus soleus muscles, which remain unaltered in *mdx* and *mdx*/mTR mice. Of note, γ~cyto~-actin staining was markedly brighter in TA and soleus muscles from *mdx* and *mdx*/mTR mice ([Figure 8](#F8){ref-type="fig"}), consistent with increased γ~cyto~-actin levels in dystrophic muscles ([@B30], [@B29]). Both increased γ~cyto~-actin and correspondingly increased Tmod3 levels were confirmed by Western blotting (Supplemental Figure S4). However, γ~cyto~-actin was not enriched at the Z-line or H-zone periphery in *mdx* or *mdx*/mTR muscles ([Figure 8](#F8){ref-type="fig"}), indicating no incorporation of γ~cyto~-actin into the barbed or pointed ends of the thin filaments, respectively. We conclude that depletion of sarcomeric Tmods from dystrophic skeletal muscle does not enable incorporation of γ~cyto~-actin into the thin filaments.

![γ~cyto~-Actin exhibits normal, SR-associated localization in *mdx* and *mdx*/mTR muscles. (A, B) Longitudinal cryosections of (A) TA and (B) soleus muscles from 2-mo-old WT, *mdx*, and *mdx*/mTR mice were immunostained for γ-actin and α-actinin and phalloidin-stained for F-actin. M, M-line; Z, Z-line. Bars, 1 μm.](852fig8){#F8}

DISCUSSION
==========

We identified calpain-mediated proteolysis of sarcomeric Tmods and resultant elongation of thin filaments from their pointed ends in skeletal muscles from murine models of DMD. Two factors influence this mechanism: 1) disease severity (low vs. high in *mdx* vs. *mdx*/mTR muscles, respectively), and 2) muscle recruitment and use (infrequent vs. frequent in TA vs. soleus muscles, respectively). By systematically analyzing Tmod isoform localizations and levels, we showed that *mdx* soleus and *mdx*/mTR TA muscles lose only Tmod1 via calpain-mediated proteolysis, whereas *mdx*/mTR soleus muscle loses both Tmod1 and Tmod4 (summarized in [Figure 9](#F9){ref-type="fig"}). Thus dystrophic muscle provides a useful experimental system in which to study thin filament length regulation by sarcomeric Tmods and suggests that misspecification of thin filament length may contribute to muscle pathology in DMD. Note that the observed relationship between elevated m-calpain levels and Tmod proteolysis is correlative and not necessarily causative. Other proteolytic pathways may also contribute to Tmod proteolysis in DMD.

![Model of pointed-end capping by sarcomeric Tmods and thin filament elongation in dystrophic skeletal muscle. TA and soleus muscles differ by their fiber type distributions, recruitment levels, and thin filament (distal segment) lengths. In *mdx* mice (mild dystrophy), soleus muscle exhibits depletion of Tmod1 and thin filament elongation. In *mdx*/mTR mice (severe dystrophy), TA muscle exhibits depletion of Tmod1, soleus muscle exhibits depletion of both Tmod1 and Tmod4, and both TA and soleus exhibit thin filament elongation. For simplicity, one actin strand, one nebulin molecule, one tropomyosin polymer, and one Tmod molecule are depicted for each thin filament. Also for simplicity, equal proportions of Tmod1 and Tmod4 are depicted for each WT sarcomere.](852fig9){#F9}

Implications for thin filament length regulation in skeletal muscle
-------------------------------------------------------------------

In *Drosophila* and vertebrate cardiac muscles, thin filaments lack nebulin, and thin filament lengths are inversely related to the extent of pointed-end capping by sarcomeric Tmods, with greater capping yielding shorter lengths and reduced capping yielding longer lengths ([@B28]; [@B58]; [@B34]; [@B37]; [@B21]). By contrast, in skeletal muscle, thin filaments contain nebulin and are divided into two structurally distinct segments: 1) a constant-length, nebulin-coated proximal segment anchored at the Z-line, and 2) a variable-length, nebulin-free distal segment capped by sarcomeric Tmods at the H-zone periphery ([@B22]). This study identifies *mdx* and *mdx*/mTR mice as the first in vivo models of Tmod isoform depletion leading to thin filament elongation in skeletal muscle, demonstrating that the lengths of the nebulin-free distal segments of skeletal muscle thin filaments are regulated by sarcomeric Tmods via a similar inverse manner as the nebulin-free thin filaments in *Drosophila* and vertebrate cardiac muscles. A corollary of this conclusion is that the nebulin-free thin filaments in *Drosophila* and vertebrate cardiac muscles are effectively "ultralong distal segments" lacking nebulin-coated proximal segments ([@B22]).

Intriguingly, comparison of WT, *mdx*, and *mdx*/mTR soleus muscles reveals that graded losses of sarcomeric Tmod isoforms do not result in correspondingly graded increases in thin filament lengths. Namely, *mdx* soleus (lacking Tmod1) and *mdx*/mTR soleus (lacking both Tmod1 and Tmod4) have statistically indistinguishable thin filament lengths of 1.28 ± 0.09 and 1.29 ± 0.06 μm, respectively. The additional loss of Tmod4 from *mdx*/mTR soleus without a further increase in thin filament length, as compared with *mdx* soleus, where only Tmod1 is lost, also suggests unique functions for Tmod1 and Tmod4 in sarcomeres. Whereas Tmod1 is clearly important for length regulation, Tmod4 appears to be less important and may instead play a role in regulating actomyosin contractility (see later discussion). Previous studies using quantitative immunoprecipitation with pan-Tmod antibodies led to the conclusion that there are 1.2--1.6 Tmods/thin filament in rat psoas muscles ([@B16]). However, based on the quantitative Western blotting experiments presented here, Tmod1 is an order of magnitude less abundant than Tmod4 in sarcomeres, and ∼2 Tmods cap each thin filament in mouse skeletal muscles. Nevertheless, loss of Tmod1 in the *mdx* soleus can still result in an increase in average thin filament length, even when the protein levels and immunostaining pattern of the more abundant Tmod4 isoform remain unchanged. Calculations of sarcomeric Tmod concentrations based on 2 Tmods/pointed end (this study), a mouse skeletal muscle α-actin concentration of 893 μM ([@B30]), and subcellular fractionation of mouse skeletal muscle showing ∼50% of Tmod1 and Tmod4 associated with myofibrils ([@B20]) yield a total sarcomeric Tmod concentration of ∼9.2 μM and a Tmod1 concentration of just 0.92 μM. Therefore, even when ∼50% of the Tmod1 is degraded in the *mdx* soleus, total Tmod is reduced by just 5%. Thus it is surprising that the more abundant Tmod4 fails to occupy the vacant ends formerly occupied by Tmod1 in the *mdx* soleus. This is not because the cytosolic concentration of sarcomeric Tmods (∼1.84 μM) is below the *K*~d~ of Tmod1 or Tmod4 binding to tropomyosin-coated actin filaments (∼10 pM; [@B2]; [@B63]). A consequence of this is that the cytosolic subpopulations of Tmod1 and Tmod4 are unlikely to freely exchange with the thin filament pointed-end populations. We speculate that, instead, thin filament--associated Tmod4 dynamically shuttles among adjacent pointed ends to regulate thin filament lengths within a sarcomere, similar to a proposed mechanism of Tmod1 dynamics in cardiac myocytes ([@B34]). Therefore, when Tmod1 is depleted, a reduced ratio of total Tmod to pointed ends can lead to actin subunit addition and longer thin filaments in skeletal muscle, similar to observations in cardiac and *Drosophila* muscle ([@B28]; [@B58]; [@B34]; [@B37]; [@B4]).

Our findings further show that uniformity of thin filament lengths is well regulated in the *mdx*/mTR soleus, even when both Tmod1 and Tmod4 are depleted and thin filament lengths increase by ∼12%. This implies the existence of additional structural and/or regulatory constraints that restrict uncontrolled elongation of thin filaments from their pointed ends. Two such potential constraints are 1) limited availability of actin monomers in the cytosol ([@B55]) and 2) pointed ends interacting with as-yet-unidentified M-line or H-zone constituents ([@B22]). It is noteworthy that *mdx*/mTR soleus muscle also exhibits occasional patches of myofibril degeneration and disorganization, and we cannot exclude the possibility that any "overly long" thin filaments that appear in the *mdx*/mTR soleus may be transient or unstable, subsequently disassembling via ADF/cofilin-mediated actin depolymerization ([@B43]; [@B45]; [@B40]) or some other disassembly mechanism. Such disassembly would be reminiscent of---but not identical to---observations in cultured cardiomyocytes, in which antibody inhibition of Tmod1/tropomyosin binding leads to thin filament disassembly ([@B42]).

In *Tmod1^−/−^* mouse skeletal muscle, thin filament lengths are normal because Tmod3 structurally compensates for the absence of Tmod1 by dissociating from its SR-associated compartment and redistributing to the thin filament pointed ends ([@B24]; [@B20]). However, Tmod3 fails to compensate for depletion of Tmod1 (and Tmod4) in dystrophic muscle. The most likely explanation for this discrepancy is that Tmod3 can only assemble in the complete absence of Tmod1 during muscle development, prior to Tmod3 associating with its binding partners in the SR. It appears that, in *Tmod1^−/−^* muscle, absence of Tmod1 eliminates the competition between Tmod1 and Tmod3 for the striated muscle tropomyosins at the pointed ends ([@B24]), thereby enabling Tmod3 to aberrantly assemble onto the thin filament pointed ends. By contrast, in adult *mdx* and *mdx*/mTR muscle, Tmod3 is already associated with the pointed ends of γ~cyto~-actin filaments in the SR-associated cytoskeletal network before the onset of muscle damage ([@B20]). Thus, even as contraction-induced sarcolemmal rupture leads to Ca^2+^ influx, calpain activation, and proteolytic depletion of sarcomeric Tmods in *mdx* and *mdx*/mTR muscles, Tmod3's interactions with its SR-associated binding partners may render it unable to translocate to the thin filament pointed ends. Indeed, stable association of Tmod3 with the SR is supported by its resistance to proteolysis in *mdx* and *mdx*/mTR muscles.

Implications for DMD pathology
------------------------------

Thin filament elongation due to depletion of sarcomeric Tmods in *mdx* and *mdx*/mTR muscles indicates that secondary, myofibril-intrinsic changes are likely to contribute to muscle weakness in DMD, occurring in conjunction with the primary changes directly resulting from dystrophin deficiency (i.e., sarcolemmal fragility and impaired lateral force transmission). First, sliding filament theory predicts that thin filament elongation due to depletion of sarcomeric Tmods will result in a widening and rightward shift in the sarcomere length--tension relationship and increased optimum sarcomere length for force production in *mdx* and *mdx*/mTR muscles ([@B27]; [@B22]). However, physiological experiments have shown no such changes in *mdx* muscles ([@B12]). The most likely explanation for this discrepancy is that the thin filament length changes observed in *mdx* and *mdx*/mTR muscles are too small to induce measurable changes in the sarcomere length--tension curve, especially given the experimental variability associated with conventional physiological assays. Indeed, physiological analyses of skeletal muscles from perch fish, *nebulin^−/−^* mice, and human nemaline myopathy patients have shown that thin filament length changes of as much as 0.30 μm may be required to significantly alter the sarcomere length--tension curve ([@B27]; [@B19]; [@B47], [@B46]). Such thin filament length changes are markedly greater than the thin filament length changes of ∼0.15 μm observed in this study.

Second, depletion of sarcomeric Tmods may inhibit the formation of productive actomyosin cross-bridges in *mdx* and *mdx*/mTR muscles. Skinned fiber mechanics and x-ray diffraction studies of *Tmod1^−/−^* muscles reveal reduced tropomyosin strand movement and actomyosin cross-bridge recruitment during thin filament activation ([@B44]). Although the biophysical mechanism is not understood, Tmod1's interactions with F-actin and/or terminal tropomyosins at the pointed end may mediate a long-range conformational change in the thin filament that facilitates cross-bridge recruitment. Tmod4 may also play its own as-yet-undetermined role in regulating thin filament activation and/or cross-bridge recruitment, distinct from Tmod1. Thus we might expect sarcomeric Tmod-depleted fibers from *mdx* and *mdx*/mTR muscles to also exhibit attenuated thin filament activation and impaired cross-bridge recruitment. Future studies will be required to explore this prediction experimentally using skinned fiber mechanics with *mdx*/mTR TA muscles, as soleus muscles are unsuitable for skinned fiber mechanics. However, based on this prediction, it is tempting to speculate that increasing actomyosin contractility via pharmacological interventions (e.g., troponin activators) may ameliorate muscle weakness in DMD. Such a strategy should be approached with caution, because increased actomyosin contractility has the potential to exacerbate sarcolemmal damage in dystrophic muscle, thereby canceling out any potentially beneficial effect of the increased actomyosin contractility. Preclinical studies using dystrophic mouse models are underway in order to resolve this dilemma ([@B39]).

Although it has been established that calpain-mediated proteolysis contributes to skeletal muscle degeneration in DMD ([@B57]; [@B56]; [@B59]), identifying the molecular mechanisms of calpain function in vivo has been challenging due to the paucity of confirmed calpain substrates and the widely variable amino acid sequences surrounding calpain cleavage sites ([@B8]; [@B25]). Calpains generally favor cytoskeletal proteins, including F-actin--associated proteins, such as spectrin (reviewed in [@B14]), filamin ([@B64]), and cortactin ([@B48]). Calpain also proteolyzes utrophin ([@B13]), a dystrophin homologue and actin-binding protein that compensates for dystrophin deficiency in *mdx* mouse muscle but not human DMD ([@B33]; [@B15]; [@B26]; [@B18]; [@B51], [@B50]). These observations, in conjunction with our findings that m-calpain proteolyzes sarcomeric Tmods in *mdx* and *mdx*/mTR muscles, collectively suggest that F-actin remodeling is an important contributor to muscle dysfunction in DMD. Our findings also implicate Tmods as potential calpain cleavage targets in other pathological events characterized by heightened calpain activity, such as traumatic brain injury, stroke, and myocardial infarction ([@B8]; [@B25]). Future studies will seek to examine such Tmod proteolysis and F-actin remodeling in human patients.

MATERIALS AND METHODS
=====================

Experimental animals
--------------------

WT and *mdx* mice were obtained from the Jackson Laboratory (Bar Harbor, ME). The *mdx*/mTR mice have been described previously ([@B52]). The *mdx*/mTR mice were bred for two generations to minimize telomere length while maintaining mouse viability, as described previously ([@B52]; [@B41]). Because DMD is an X-linked disorder, experiments were restricted to male mice. Mice were either 2 wk or 2 mo old at the time of killing, corresponding to time points before or after the onset of muscle necrosis, respectively ([@B3]; [@B12]). Mice were killed by isoflurane inhalation followed by cervical dislocation. All procedures were performed in accordance with animal care guidelines enforced by the Institutional Animal Care and Use Committee at the Scripps Research Institute.

Antibodies
----------

Primary antibodies and dilutions were as follows: affinity-purified rabbit polyclonal anti-human Tmod1 (R1749bl3c, 3.1 μg/ml for cryosections, 0.31 μg/ml for isolated myofibrils; [@B24]), rabbit polyclonal antiserum to residues 340--359 of a human Tmod1 peptide (PA2211, 1:5000 for Western blots; [@B23]), rabbit polyclonal antiserum to chicken Tmod4 preadsorbed by passage through a Tmod1 Sepharose column (R3577bl3c, 1:25 for cryosections, 1:250 for isolated myofibrils, 1:2500 for Western blots; [@B24]), rabbit polyclonal antiserum to human Tmod3 preadsorbed by passage through a Tmod1 Sepharose column (R5168bl3c, 1:100 for cryosections, 1:1000 for Western blots; [@B24]), affinity-purified rabbit polyclonal anti--nebulin M1M2M3 domain (R1357L, 9.3 μg/ml for cryosections; a gift from Carol C. Gregorio, University of Arizona, Tucson, AZ), affinity-purified rabbit polyclonal anti-γ~cyto~-actin (7577, 0.9 μg/ml for cryosections, 0.09 μg/ml for Western blots; a gift from James M. Ervasti, University of Minnesota, Minneapolis, MN), mouse monoclonal anti--m-calpain (107-82, 1:50 for cryosections, 1:1000 for Western blots; Thermo Fisher Scientific, Waltham, MA), mouse monoclonal anti--α-actinin (EA53, 1:100 for cryosections, 1:1000 for isolated myofibrils, 1:10,000 for Western blots; Sigma-Aldrich, St. Louis, MO), mouse monoclonal anti-actin (C4, 1:10,000 for Western blots; EMD Millipore, Billerica, MA), and mouse monoclonal anti--glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1D4, 1:5000 for Western blots; Novus Biologicals, Littleton, CO). Secondary antibodies and dilutions were as follows: Alexa Fluor 488--conjugated goat anti-rabbit immunoglobulin G (IgG; 1:200 for cryosections, 1:1000 for isolated myofibrils; Life Technologies, Carlsbad, CA), Alexa Fluor 647--conjugated goat anti-mouse IgG (1:200 for cryosections, 1:1000 for isolated myofibrils; Life Technologies), 800CW-conjugated goat anti-rabbit IgG (1:20,000 for Western blots; LI-COR Biosciences, Lincoln, NE), and 680LT-conjugated goat anti-mouse IgG (1:20,000 for Western blots; LI-COR Biosciences).

Preparation and immunostaining of isolated myofibrils
-----------------------------------------------------

Myofibril preparation procedures were modified from those described previously ([@B32]; [@B9]). Briefly, two TA and two EDL muscles were excised from mouse hindlimbs, stretched, pinned to cork, and relaxed overnight in ice-cold relaxing buffer (100 mM NaCl, 2 mM KCl, 2 mM MgCl~2~, 6 mM K~3~PO~4~, 1 mM ethylene glycol tetraacetic acid \[EGTA\], 0.1% glucose, pH 7.0) supplemented with protease inhibitor cocktail (1:1000; Life Technologies). TA and EDL tissues were pooled due to their functional similarity and nearly identical fiber type distributions ([@B7]). Muscles were then transferred to ice-cold rigor buffer (100 mM KCl, 10 mM K~3~PO~4~, 2 mM MgCl~2~, 1 mM EGTA, pH 7.0) for 10 min, placed in a conical tube containing 5 ml of rigor buffer and protease inhibitor cocktail (1:1000; Life Technologies), and homogenized with a Tekmar Tissumizer at 70% of maximum speed for 90 s. The homogenate was then centrifuged at 1000 × *g* for 5 min, the supernatant was decanted, and myofibrils were resuspended in ice-cold rigor buffer. Centrifugation/resuspension was repeated three times to clean the myofibril suspension (∼10:1 buffer:myofibrils after washing), which was then divided into aliquots, to which 10 mM CaCl~2~ and increasing concentrations of m-calpain (BioVendor, Asheville, NC) ± 10 μg/ml calpeptin (Enzo Life Sciences, Farmingdale, NY) were added. Myofibril suspensions were incubated for 1 h at room temperature, dropped onto poly-[l]{.smallcaps}-lysine--coated microscope slides (Polysciences, Warrington, PA), and allowed to adhere for 30 min. Adherent myofibrils were then fixed for 30 min in 4% paraformaldehyde (PFA) in rigor buffer, washed for 5 min in phosphate-buffered saline (PBS) plus 0.1% Triton X-100 (PBST), and then blocked for 1 h in 4% bovine serum albumin (BSA) plus 1% goat serum in PBST at room temperature. Myofibrils were then labeled with primary antibodies diluted in blocking buffer for 1 h at room temperature, washed for 5 min in PBST, and labeled with a fluorophore-conjugated secondary antibody mixture in blocking buffer for 1 h at room temperature. The secondary antibody mixture was supplemented with rhodamine--phalloidin (1:500; Life Technologies) to stain F-actin. Myofibrils were then washed again in PBST, preserved in Gel Mount aqueous mounting medium (Sigma-Aldrich), and coverslipped.

Preparation and immunostaining of muscle tissue cryosections
------------------------------------------------------------

Mouse hindlimbs were pinned to cork, immersed in ice-cold relaxing buffer, relaxed for 24 h at 4°C, and then fixed in 4% PFA in relaxing buffer for 24 h at 4°C. TA and soleus muscles were then excised, cryoprotected in 30% sucrose in PBS for 4 h, embedded in Tissue-Tek OCT Compound (Sakura Finetek USA, Torrance, CA), and frozen on a metal block chilled in liquid N~2~. Muscles were divided into 12-μm-thick cryosections, mounted on slides, and stored at −20°C until use. Sections were washed in PBST, permeabilized for 15 min in PBS plus 0.3% Triton X-100, and blocked for 2 h in 4% BSA plus 1% goat serum in PBST. Tissues were labeled with primary antibodies diluted in blocking buffer overnight at 4°C, washed three times in PBST, and then labeled with a fluorophore-conjugated secondary antibody mixture in blocking buffer for 2 h at room temperature. The secondary antibody mixture was supplemented with rhodamine--phalloidin (1:100; Life Technologies) to stain F-actin. Tissues were then washed three times in PBST, preserved in Gel Mount aqueous mounting medium (Sigma-Aldrich), and coverslipped.

Confocal imaging
----------------

Images of single optical sections were collected on a Bio-Rad Radiance 2100 laser-scanning confocal microscope (Bio-Rad, Hercules, CA) mounted on a Nikon TE2000-U microscope (Nikon, Melville, NY) using a 100× (1.4 numerical aperture) Plan-Apochromat oil-objective lens at room temperature (zoom = 3). Bio-Rad LaserSharp 2000 software was used during image collection. Images were processed with Photoshop (Adobe, San Jose, CA), and image figures were constructed in Adobe Illustrator. Supplemental Figure S5 shows diagrams of sarcomeres indicating the expected locations of the various fluorescently labeled proteins in [Figures 4--8](#F4 F5 F6 F7 F8){ref-type="fig"}.

Thin filament length measurements
---------------------------------

DDecon was used to measure distances of Tmod1 and Tmod4 from the Z-line as well as the breadth of the F-actin (phalloidin) signal across the Z-lines of adjacent half-sarcomeres (I-Z-I arrays; [@B35]). Analysis was performed using a DDecon plug-in originally developed for ImageJ (National Institutes of Health, Bethesda, MD) by Ryan S. Littlefield (University of Washington, Seattle, WA) and modified by Zhen Ren (The Scripps Research Institute, La Jolla, CA). This plug-in is available for public download at <http://www.scripps.edu/fowler/>. The DDecon plug-in generates the best fit of a model intensity distribution function for a given thin filament component (Tmod or F-actin) to an experimental one-dimensional myofibril fluorescence intensity profile (line scan) of three thin filament arrays obtained for each fluorescent probe (anti-Tmod or phalloidin; [@B35]). Model fitting of background-corrected line scans was optimized by an iterative fitting procedure that minimizes the error between the observed line-scan intensities and the modeled intensities, using a multivariate line-fitting algorithm, as described previously ([@B35]). Distances were calculated by converting pixel sizes into micrometers based on each image\'s magnification factor (25.6 pixels/μm).

Western blotting
----------------

For Western blots of whole-muscle homogenates, TA, EDL, and soleus muscles were dissected in ice-cold PBS and homogenized with a Tekmar Tissumizer in 10 volumes of PBS supplemented with protease inhibitor cocktail (1:1000; Life Technologies). For Western blots of isolated myofibrils, myofibril suspensions were prepared as described under *Preparation and immunostaining of isolated myofibrils*. Protein standards for SDS--PAGE and Coomassie blue staining to determine actin concentrations in isolated myofibrils were prepared from rabbit skeletal muscle actin (Cytoskeleton, Denver, CO). Protein standards for quantitative Western blots were prepared by spiking increasing volumes of *Tmod1^−/−^* ([@B24]) or *Tmod4^−/−^* TA muscle homogenates with increasing amounts of recombinant purified human Tmod1 or mouse Tmod4 proteins ([@B66]), respectively. This approach equalized the effects of endogenous non-Tmod proteins on the Western transfer efficiencies of endogenous versus recombinant purified Tmods. (The *Tmod4^−/−^* mouse was made from mouse embryonic stem cells with a *lacZ*/*neo* insertion in exon 2 of the *Tmod4* gene, and its phenotype will be described in detail elsewhere.)

Muscles, myofibrils, and purified protein preparations were solubilized in an equal volume of 2× SDS sample buffer and boiled for 5 min. Proteins were separated via SDS--PAGE on 4--20% Tris-glycine gradient minigels for 1 h at 200 V and transferred to nitrocellulose (pore size, 0.2 μm), as described previously ([@B24]). Blots were stained with 0.2% Ponceau S in 3% trichloroacetic acid to verify protein transfer, blocked for 2 h in 4% BSA plus 1% goat serum in PBS at room temperature, and then incubated in primary antibodies diluted in Blitz buffer (4% BSA, 10 mM NaHPO~4~, 150 mM NaCl, 1 mM EDTA, 0.2% Triton X-100, pH 7.4) overnight at 4°C. After washing in PBST, blots were incubated in secondary antibodies diluted in Blitz for 1 h at room temperature. After washing again in PBST, bands were visualized using a LI-COR Odyssey infrared imaging system and densitometrically quantified using ImageJ (with normalization to GAPDH, where appropriate).

RT-PCR
------

Total RNA was extracted from frozen TA, EDL, and soleus muscles using TRIzol reagent (Qiagen, Valencia, CA) and reverse transcribed using oligo(dT) primers and M-MLV reverse transcriptase (Life Technologies), according to the manufacturer\'s instructions. Primers were as follows: *Tmod1* sense, 5′-CAACGCCATGATGAGCAAC-3′; *Tmod1* antisense, 5′-CATCGGTAGAACACGTCCAG-3′; *Tmod4* sense, 5′-GATGCGGTAGAGATGGAGATG-3′; *Tmod4* antisense, 5′-TCTCTT­CTTTTGCTGACGACG-3′; *GAPDH* sense, 5′-GGGCATCTTGGGCT­ACACT-3′; and *GAPDH* antisense, 5′-GAGCAATGCCAGCCCCG-3′. PCR was then performed using a Bio-Rad T100 thermal cycler. An initial hold at 95°C for 1 min was followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, and extension at 72°C for 20 s. After a final hold at 72°C for 5 min, reaction products were electrophoresed on agarose gels, stained with EtBr, and visualized using a MultiImage Light Cabinet (Alpha Innotech, San Leandro, CA). *Tmod1* and *Tmod4* band intensities were densitometrically quantified using ImageJ with normalization to *GAPDH*.

In vitro proteolysis
--------------------

Recombinant human Tmod1 and mouse Tmod4 were purified as described previously ([@B66]). Increasing concentrations of m-calpain were mixed with 3 μg of Tmod1 or Tmod4 in a final volume of 10 μl, and mixtures were then incubated for 1 h at room temperature, solubilized in an equal volume of 2× SDS sample buffer, and boiled for 5 min. Proteins were separated via SDS--PAGE on 4--20% Tris-glycine gradient minigels for 1 h at 200 V. Gels were then stained with Coomassie blue for 10 min, destained overnight, scanned at 600 dpi, and densitometrically quantified using ImageJ.

Statistics
----------

Data are presented as either mean ± SD or mean ± SEM, where appropriate. Differences between two groups were detected using Student\'s *t* test. Differences between three groups were detected using one-way analysis of variance with post hoc Fisher\'s PLSD tests. Statistical significance was defined as *p* \< 0.05. Statistical analysis was performed in Excel (Microsoft, Redmond, WA).
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